| Name | Title | Contact Details |
|---|
Find the most effective and affordable therapy, counseling, and treatments with Foresight! With our advanced technology, we make sure to provide the most effective and accurate treatment to our patients. We accept most insurances, so book today and sta...
Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.
Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.
EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.